Literature DB >> 15190457

Genotype-phenotype correlations for nervous system tumors in neurofibromatosis 2: a population-based study.

Michael E Baser1, Lisa Kuramoto, Harry Joe, J M Friedman, Andrew J Wallace, James E Gillespie, Richard T Ramsden, D Gareth R Evans.   

Abstract

Neurofibromatosis 2 (NF2) is an autosomal dominant disease that is characterized by tumors on the vestibular branch of the VIII cranial nerve, but other types of nervous system tumors usually occur as well. Genotype-phenotype correlations are well documented for overall NF2 disease severity but have not been definitively evaluated for specific types of non-VIII nerve tumors. We evaluated genotype-phenotype correlations for various types of non-VIII nerve tumors in 406 patients from the population-based United Kingdom NF2 registry, using regression models with the additional covariates of current age and type of treatment center (specialty or nonspecialty). The models also permitted consideration of intrafamilial correlation. We found statistically significant genotype-phenotype correlations for intracranial meningiomas, spinal tumors, and peripheral nerve tumors. People with constitutional NF2 missense mutations, splice-site mutations, large deletions, or somatic mosaicism had significantly fewer tumors than did people with constitutional nonsense or frameshift NF2 mutations. In addition, there were significant intrafamilial correlations for intracranial meningiomas and spinal tumors, after adjustment for the type of constitutional NF2 mutation. The type of constitutional NF2 mutation is an important determinant of the number of NF2-associated intracranial meningiomas, spinal tumors, and peripheral nerve tumors.

Entities:  

Mesh:

Year:  2004        PMID: 15190457      PMCID: PMC1216057          DOI: 10.1086/422700

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  42 in total

1.  Phenotypic variability in two families with novel splice-site and frameshift NF2 mutations.

Authors:  V F Mautner; M E Baser; L Kluwe
Journal:  Hum Genet       Date:  1996-08       Impact factor: 4.132

2.  Phenotypic variability associated with 14 splice-site mutations in the NF2 gene.

Authors:  L Kluwe; M MacCollin; M Tatagiba; S Thomas; W Hazim; W Haase; V F Mautner
Journal:  Am J Med Genet       Date:  1998-05-18

3.  Identification of NF2 germ-line mutations and comparison with neurofibromatosis 2 phenotypes.

Authors:  L Kluwe; S Bayer; M E Baser; W Hazim; W Haase; C Fünsterer; V F Mautner
Journal:  Hum Genet       Date:  1996-11       Impact factor: 4.132

4.  Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities.

Authors:  D M Parry; M M MacCollin; M I Kaiser-Kupfer; K Pulaski; H S Nicholson; M Bolesta; R Eldridge; J F Gusella
Journal:  Am J Hum Genet       Date:  1996-09       Impact factor: 11.025

5.  Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease.

Authors:  M H Ruttledge; A A Andermann; C M Phelan; J O Claudio; F Y Han; N Chretien; S Rangaratnam; M MacCollin; P Short; D Parry; V Michels; V M Riccardi; R Weksberg; K Kitamura; J M Bradburn; B D Hall; P Propping; G A Rouleau
Journal:  Am J Hum Genet       Date:  1996-08       Impact factor: 11.025

6.  A missense mutation in the neurofibromatosis 2 gene occurs in patients with mild and severe phenotypes.

Authors:  D R Scoles; M E Baser; S M Pulst
Journal:  Neurology       Date:  1996-08       Impact factor: 9.910

7.  Neurofibromatosis 2 tumour suppressor schwannomin interacts with betaII-spectrin.

Authors:  D R Scoles; D P Huynh; P A Morcos; E R Coulsell; N G Robinson; F Tamanoi; S M Pulst
Journal:  Nat Genet       Date:  1998-04       Impact factor: 38.330

8.  Skin abnormalities in neurofibromatosis 2.

Authors:  V F Mautner; M Lindenau; M E Baser; L Kluwe; J Gottschalk
Journal:  Arch Dermatol       Date:  1997-12

9.  Accurate diagnosis of carriers of deletions and duplications in Duchenne/Becker muscular dystrophy by fluorescent dosage analysis.

Authors:  S C Yau; M Bobrow; C G Mathew; S J Abbs
Journal:  J Med Genet       Date:  1996-07       Impact factor: 6.318

10.  Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations.

Authors:  D G Evans; L Trueman; A Wallace; S Collins; T Strachan
Journal:  J Med Genet       Date:  1998-06       Impact factor: 6.318

View more
  22 in total

Review 1.  Somatic mosaicism: on the road to cancer.

Authors:  Luis C Fernández; Miguel Torres; Francisco X Real
Journal:  Nat Rev Cancer       Date:  2015-12-18       Impact factor: 60.716

Review 2.  Neurofibromatosis type 2.

Authors:  Ashok R Asthagiri; Dilys M Parry; John A Butman; H Jeffrey Kim; Ekaterini T Tsilou; Zhengping Zhuang; Russell R Lonser
Journal:  Lancet       Date:  2009-05-22       Impact factor: 79.321

Review 3.  The location of constitutional neurofibromatosis 2 (NF2) splice site mutations is associated with the severity of NF2.

Authors:  M E Baser; L Kuramoto; R Woods; H Joe; J M Friedman; A J Wallace; R T Ramsden; S Olschwang; E Bijlsma; M Kalamarides; L Papi; R Kato; J Carroll; C Lázaro; F Joncourt; D M Parry; G A Rouleau; D G R Evans
Journal:  J Med Genet       Date:  2005-07       Impact factor: 6.318

Review 4.  News on the genetics, epidemiology, medical care and translational research of Schwannomas.

Authors:  C O Hanemann; D G Evans
Journal:  J Neurol       Date:  2006-12       Impact factor: 4.849

5.  A deletion causing NF2 exon 9 skipping is associated with familial autosomal dominant intramedullary ependymoma.

Authors:  Ilyess Zemmoura; Patrick Vourc'h; Agathe Paubel; Béatrice Parfait; Joëlle Cohen; Frédéric Bilan; Alain Kitzis; Cécilia Rousselot; Fabrice Parker; Patrick François; Christian R Andres
Journal:  Neuro Oncol       Date:  2013-12-18       Impact factor: 12.300

Review 6.  Hereditary genodermatoses with cancer predisposition.

Authors:  Meg R Gerstenblith; Alisa M Goldstein; Margaret A Tucker
Journal:  Hematol Oncol Clin North Am       Date:  2010-10       Impact factor: 3.722

Review 7.  Methodological issues in longitudinal studies: vestibular schwannoma growth rates in neurofibromatosis 2.

Authors:  M E Baser; V-F Mautner; D M Parry; D G R Evans
Journal:  J Med Genet       Date:  2005-04-14       Impact factor: 6.318

8.  Age related shift in the mutation spectra of germline and somatic NF2 mutations: hypothetical role of DNA repair mechanisms.

Authors:  D G R Evans; E R Maher; M E Baser
Journal:  J Med Genet       Date:  2005-08       Impact factor: 6.318

9.  Therapeutic potential of HSP90 inhibition for neurofibromatosis type 2.

Authors:  Karo Tanaka; Ascia Eskin; Fabrice Chareyre; Walter J Jessen; Jan Manent; Michiko Niwa-Kawakita; Ruihong Chen; Cory H White; Jeremie Vitte; Zahara M Jaffer; Stanley F Nelson; Allan E Rubenstein; Marco Giovannini
Journal:  Clin Cancer Res       Date:  2013-05-28       Impact factor: 12.531

Review 10.  Neurofibromatosis type 2 (NF2): a clinical and molecular review.

Authors:  D Gareth R Evans
Journal:  Orphanet J Rare Dis       Date:  2009-06-19       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.